Early Onset Preeclampsia Dinner Symposium
Feb. 4, 2016 7 - 9:30pm
Early Onset Preeclampsia (EOP) defined as Preeclampsia arising before 34 weeks gestational age is a rare but extremely critical condition occurring in about 0.3% of all pregnancies. Growth (% change) in the incidence of EOP is outpacing other types of preeclampsia, and other modern public health challenges including diabetes and Alzheimer’s disease. EOP is particularly vexing as it is one of the leading causes of prematurity in the United States and Worldwide. While expectant management in selected patients has now become “standard of care” many controversies regarding the diagnosis and management remain. In addition, many new therapies are currently in development which could ultimately impact medical practice of this difficult to manage condition.
· Introductions and Learning Objectives - Baha Sibai, MD
· Epidemiology of EOP and Natural History of Expectant Management -Amelia Sutton, MD
· Burden of EOP: Mother and Newborn Outcomes - Michael Paidas, MD
· Biomarkers to Predict Adverse Outcomes During Expectant Management - TBA
· Novel Therapies for the Treatment of EOP - Baha Sibai, MD
· Open Discussion on Key Issues in Expectant Management – Faculty and Audience
This program is supported by a generous, unrestricted educational grant from rEVO Biologics.
The content of this non-CME educational symposium was developed independently with the goal of ensuring regulatory compliance to support initiatives that accelerate the translation of clinical science into quality patient care.
132 people registered | 0 spots left